Approval · Notice of Compliance 33234 · 2024
MYLAN-VALACYCLOVIR: Notice of Compliance 33234
Issued May 16, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33234
- Date
- May 16, 2024
- Company
- Mylan Pharmaceuticals UlcEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Labels
- Canadian reference product
- VALTREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MYLAN-VALACYCLOVIR | Not yet assigned | — |
Medicinal ingredients
- VALACYCLOVIR HYDROCHLORIDE 500 MG per TAB
- VALACYCLOVIR HYDROCHLORIDE 1,000 MG per TAB